UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 21, 2012

CBRE GROUP, INC.

(Exact name of registrant as specified in its charter)

(310) 405-8900

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

This Current Report on Form 8-K is filed by CBRE Group, Inc., a Delaware corporation (which we may refer to as “we”, “us”, “our” or the “Company”), in connection with the matters described herein:

On December 21, 2012, the Board of Directors (the “Board”) of the Company increased the size of the Board from 11 to 12 directors and the Company entered into a Nomination and Standstill Agreement (the “Agreement”), dated December 21, 2012, by and among VA Partners I, LLC, ValueAct Capital Master Fund, L.P., ValueAct Capital Management, L.P., ValueAct Capital Management, LLC, ValueAct Holdings, L.P., ValueAct Holdings GP, LLC, and Brandon B. Boze (collectively, the “ValueAct Group”). The ValueAct Group represented in the Agreement that as of December 21, 2012, it collectively owned an aggregate of 32.0 million shares, or approximately 9.72% of the outstanding common stock of the Company.

Pursuant to the Agreement, the Board appointed Mr. Boze to the Company’s Board, effective immediately, to serve until the Company’s 2013 annual meeting of shareholders, or annual meeting. The Company also agreed to nominate Mr. Boze for election to the Board at the Company’s 2013 annual meeting. In the event Mr. Boze resigns or is otherwise removed or his nomination for the 2013 annual meeting is withdrawn, the Company will work in good faith with the ValueAct Group to appoint a mutually acceptable replacement nominee who meets the Company’s historical standards and criteria, so long as the ValueAct Group then owns at least 7.5% of the outstanding common stock of the Company.

Mr. Boze has agreed, while serving as a member of the Board, to (i) meet all director independence and other standards of the Company, the New York Stock Exchange and the Securities and Exchange Commission, (ii) remain qualified to serve as a director under the Delaware General Corporation Law, (iii) comply with Company policies, procedures, standards and guidelines applicable to members of the Board and (iv) preserve the confidentiality of Company business and information, including discussions in Board or committee meetings.

The Company’s obligations under the Agreement will cease, and Mr. Boze (or his replacement) must offer to resign from the Board if the ValueAct Group ceases to beneficially own at least 7.5% of the Company’s common stock, a member of the ValueAct Group breaches the Agreement, or Mr. Boze (or his replacement) ceases to meet the requirements for Board service.

The Agreement terminates on the date that is the earliest of: (1) the date that is 10 days following the date that the Company materially breaches its nomination obligations under the Agreement; (2) the date that is three months after the date Mr. Boze (or his replacement) ceases to be a member of the Board and is not replaced; (3) the date of the 2014 annual meeting; and (4) if the Company does not include Mr. Boze (or his replacement) in its slate of nominees for the Company’s 2014 annual meeting of stockholders, the date Mr. Boze (or his replacement) ceases to be a member of the Board (the “Termination Date”).

During the term of the Agreement, the ValueAct Group agrees, subject to certain exceptions, that it shall not:

-2-

The Agreement contains certain other restrictions on activities by the ValueAct Group and certain of its affiliates and associates. Further, the ValueAct Group has agreed, subject to certain limited exceptions, to vote its shares in support of Company-nominated directors and otherwise in accordance with the recommendations of the Company’s Board at the 2013 annual meeting.

The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Mr. Boze has been a Vice President at ValueAct Capital since August 2005. Prior to joining ValueAct Capital, Mr. Boze worked at Lehman Brothers in a variety of positions within merchant banking, utilities investment banking and technology mergers and acquisitions. He previously served on the board of directors of Valeant Pharmaceuticals International. Mr. Boze bolds a B.E. from Vanderbilt University and is a CFA charterholder.

Mr. Boze will receive the standard compensation received by non-employee directors. This compensation arrangement was described in the Company’s definitive proxy statement on Schedule 14A filed on March 23, 2012 with the Securities and Exchange Commission.

A copy of our press release announcing the appointment of Mr. Boze to the Board is attached hereto as Exhibit 99.2.

-3-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

-4-